We treated 3xTg-AD mice for 4 months with two stable lipidized anorexigenic peptide analogues – palm11-PrRP31, and liraglutide, a glucagon-like peptide 1 (GLP-1) analogue – as well as Dpr3-ghrelin, a stable analogue of the orexigenic peptide ghrelin, and using the method of immunohistochemistry and western blot demonstrate the effects of these compounds on the development of AD-like pathology in the brain. Here, GCG is linked to Alzheimer disease.